Articles and announcements from Swing
Press Releases
Stanza demonstrated significant improvements compared to an active control on virtually all endpoints, including fibromyalgia-related well-being, pain intensity, pain interference,…
Read this Article >
Research
This month, Swing Therapeutics presented data from a real-world trial of Stanza, an FDA-cleared digital behavioral therapy for treatment of…
Read this Article >
Research
This week, Swing announced early outcomes from Swing Care, a specialty clinic dedicated to comprehensive, evidence-based fibromyalgia treatment. The results…
Read this Article >
Press Releases
SAN FRANCISCO–Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and…
Read this Article >
Swing in the News
This week, Swing Therapeutics received De Novo marketing authorization by the U.S. Food and Drug Administration (FDA) for Stanza, the…
Read this Article >
Research
Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for chronic pain conditions, announced the publication of new research data…
Read this Article >
Press Releases
Today marks an important milestone at Swing Therapeutics: Stanza, the first prescription digital therapy for fibromyalgia patients, is now commercially…
Read this Article >
Press Releases
Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced that it has…
Read this Article >
Press Releases
Swing Therapeutics announced today that the FDA has granted Breakthrough Device Designation to the company’s digital therapeutic for the management…
Read this Article >